AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,480,000 shares, a growth of 31.0% from the September 30th total of 1,130,000 shares. Based on an average daily volume of 507,600 shares, the days-to-cover ratio is presently 2.9 days.

Analyst Ratings Changes

ANGO has been the topic of several research analyst reports. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday, October 4th.

Insider Activity

In related news, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average cost of $6.03 per share, with a total value of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at $4,109,939.46. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 22,568 shares of company stock valued at $135,847 over the last three months. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently added to or reduced their stakes in the stock. Quarry LP lifted its position in AngioDynamics by 75.1% during the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 2,594 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in AngioDynamics by 9.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock valued at $199,000 after buying an additional 2,821 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in AngioDynamics by 44.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 4,780 shares during the last quarter. CWM LLC grew its stake in AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 8,832 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics in the 3rd quarter valued at about $86,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Stock Up 2.8 %

Shares of NASDAQ ANGO opened at $6.94 on Wednesday. The company’s fifty day moving average is $7.13 and its 200-day moving average is $6.68. The stock has a market cap of $277.98 million, a price-to-earnings ratio of -1.43 and a beta of 0.65. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $8.25.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) earnings per share. On average, research analysts anticipate that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.